Sunday, January 26, 2025
The Role of the Pharmacist in Palliative Care
8:00-9:30am C/G/T
Katie Maples, PharmD, Pain and Palliative Care Coordinator and Opioid
Stewardship Pharmacist, UF Health Jacksonville
Upon completion of this activity, pharmacists will be able to: Define
Palliative Care; Discuss the importance of defining goals of care throughout the
disease process; Recommend symptom management medication frequently
used at end of life; Identify common misconceptions related to medication
usage at end of life.
UAN: 0675-0000-25-006-L08-P
Upon completion of this activity, technicians will be able to: Define Palliative
Care; Discuss the importance of defining goals of care throughout the disease
process; Identify symptom management medications frequently used at the
end of life; Identify common misconceptions related to medication usage at
end of life.
UAN: 675-0000-25-006-L08-T
When Aging Isn’t So Fun: Pain Management, Polypharmacy and
Deprescribing in the Elderly
9:30-11:00am C/G/T
Paige Broccio, PharmD, BCPS, Clinical Pharmacy Specialist, Pain Management and Palliative Care
Upon completion of this activity, pharmacists will be able to: Describe
pharmacologic difference in the elderly population; Compare multimodal
pain management options in the elderly; Discuss potential ramifications of
polypharmacy; Assess potentially inappropriate medications in the elderly
population; Determine goals of deprescribing.
UAN: 0675-0000-25-007-L08-P*
Upon completion of this activity, technicians will be able to: Define
polypharmacy and the importance of deprescribing in the elderly; Differentiate
pharmacologic differences in the elderly population; Compare various pain
management options in the elderly.
UAN: 0675-0000-25-007-L08-T*
Overview of Buprenorphine
11:15-12:45pm C/G/T
Taylor Bunn PharmD, PGY-1 Pharmacy Resident, UF Health Jacksonville
Upon completion of this activity, pharmacists will be able to: Describe the
mechanism of action, formulations, and usual doses of buprenorphine; Display
areas of pharmacy interventions; Evaluate the effects of pharmacist managed
micro-induction; Review customized buprenorphine micro-inductions;
Showcase the beneficial effects for patients.
UAN: 0675-0000-25-008-L0-P*
Upon completion of this activity, technicians will be able to:
Recognize the usual doses of buprenorphine; Assess areas of pharmacy
interventions; Evaluate the effects of pharmacist managed micro-induction.
UAN: 675-0000-25-008-L08-T*
Abnormal Urine Drug Screen: What’s Next?
12:45-2:15pm C/G/T
Joseph Cammilleri, Pharm.D,. BCACP, CPE, Ambulatory Care Clinical Pharmacist, Pain Management, PGY2 Pain and Palliative Care Program Director, UF Clinical Assistant Professor, UF Health Jacksonville
Upon completion of this activity, pharmacists will be able to: Describe
common urine drug testing methods; Assess strategies for managing abnormal
results; Develop a strategy for tapering off opioid medications; Explain how to
transition a patient to buprenorphine.
UAN: 0675-0000-25-009-L08-P*
Upon completion of this activity, technicians will be able to: Describe
common urine drug testing methods; Research strategies for managing
abnormal results; Outline a strategy for tapering off opioid medications;
Translate the importance of transition to buprenorphine. Upon completion of
this activity, technicians will be able to: Describe common urine drug testing
methods; Research strategies for managing abnormal results; Outline a strategy
for tapering off opioid medications; Translate the importance of transition to
buprenorphine.
UAN: 0675-0000-25-009-L08-T*
C = Consultant CPE G = General Pharmacist CPE T = Technician CPE
No Comments